BioMarin Pharmaceutical (NASDAQ:BMRN) Downgraded by StockNews.com to “Buy”
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Sunday. Other equities analysts have also recently issued reports about the company. Bank of America lifted their price target on BioMarin Pharmaceutical from $99.00 to […]
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Sunday. Other equities analysts have also recently issued reports about the company. Bank of America lifted their price target on BioMarin Pharmaceutical from $99.00 to […]
